Program
nefextinib
Also written as “MAX-40279-01”, “MAX-40279” and “MAX-40279-01: 50mg/70mg”.
Its studies are mostly in Leukemia, Myeloid, Acute · Stomach Neoplasms · Colorectal Neoplasms, led by Maxinovel Pty..
Furthest: phase 2, since Sep 18, 20219 company-led studies, 1 open or runningNext primary completion: Sep 1, 2027 (phase 2)
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Maxinovel Pty. | 91 open or running | phase 2since Sep 18, 2021 | Jan 8, 2018 | Sep 1, 2027phase 2 · NCT07743112 |
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Jan 8, 2018First study: phase 1 study in Leukemia, Myeloid, AcuteFirst studyNCT03412292 · 30 enrolled · Australia
- Nov 28, 2019Phase 1 study in Solid TumorNCT04183764 · 30 enrolled · China
- Dec 3, 2019Phase 1 study in AMLNCT04187495 · 30 enrolled · China
- Sep 18, 2021Phase 2 study in LeukemiaNCT05061147 · 100 enrolled · China
- Nov 10, 2021Phase 2 study in Colorectal NeoplasmsNCT05130021 · 130 enrolled · China
- Apr 18, 2022Phase 2 study in Advanced / Metastatic Solid TumorsNCT05425602 · 108 enrolled
- Apr 26, 2022Phase 1 study in Solid TumorNCT05369286 · 28 enrolled · China
- May 19, 2022Phase 2 study in Stomach NeoplasmsNCT05395780 · 30 enrolled · China
- Jul 29, 2026Phase 2 study in Leukemia, Myeloid, AcuteNCT07743112 · 43 planned · China
Ahead
- Sep 1, 2027Primary completion: phase 2 study in Leukemia, Myeloid, AcuteNCT07743112
TargetBeta
FLT3 →read by rule
“An orally bioavailable inhibitor of the fibroblast growth factor receptor (FGFR) and FMS-like tyrosine kinase 3 (FLT3; CD135; STK1; FLK2), ”NCIt, by rule
Other programs on FLT3
| Program | Company | Furthest phase | Studies |
|---|---|---|---|
| jaktinibrule | Suzhou Zelgen Biopharmaceuticals | phase 3 | 31 |
| quizartinibrule | Daiichi Sankyo | phase 3 | 22 |
| gilteritinibrule | Astellas Pharma | phase 3 | 20 |
| pacritinibrule | Swedish Orphan Biovitrum | phase 3 | 18 |
| AXL/FLT3/VEGFR2 Inhibitor KC1036rule | beijing-konruns-pharmaceutical-co-ltd | phase 3 | 7 |
| flonoltinibrule | Chengdu Zenitar Biomedical Technology | phase 3 | 7 |
| FLT3 Inhibitor XY0206rule | shijiazhuang-yiling-pharmaceutical-co-ltd | phase 3 | 5 |
| Anti-FLT3/CD3 Bispecific Antibody CLN-049rule | cullinan-therapeutics-inc | phase 2 | 2 |
| flonoltinib maleaterule | Chengdu Zenitar Biomedical Technology | phase 2 | 2 |
| HPB-092rule | hangzhou-polymed-biopharmaceuticals-inc | phase 1 | 1 |
Studies
All 9 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT07743112Leukemia, Myeloid, Acute · China | 2 | Recruiting | Sep 1, 2027 | 43 |
| NCT05395780Stomach Neoplasms · China | 2 | UNKNOWN | Dec 2022 | 30 |
| NCT05369286Solid Tumor · China | 1 | UNKNOWN | May 31, 2023 | 28 |
| NCT05425602Advanced / Metastatic Solid Tumors | 2 | UNKNOWN | Dec 30, 2023 | 108 |
| NCT05130021Colorectal Neoplasms · China | 2 | UNKNOWN | May 30, 2022 | 130 |
| NCT05061147Leukemia · China | 2 | UNKNOWN | Apr 30, 2022 | 100 |
| NCT04187495AML · China | 1 | UNKNOWN | Dec 1, 2022 | 30 |
| NCT04183764Solid Tumor · China | 1 | UNKNOWN | Nov 1, 2022 | 30 |
| NCT03412292Leukemia, Myeloid, Acute · Australia | 1 | UNKNOWN | Nov 1, 2022 | 30 |
How it is read
Names in the registry
- “MAX-40279-01”, 4 entries
- “MAX-40279”, 3 entries
- “MAX-40279-01: 50mg/70mg”, 1 entry
- “"MAX-40279-01" and "Toripalimab"”, 1 entry
Codes read as this program: MAX4027901.
Conditions, from the studies’ own filings
- Leukemia, Myeloid, Acute, 3 studies
- Stomach Neoplasms, 1 study
- Colorectal Neoplasms, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.